Sophie Postel‐Vinay

12.8k citations
117 papers · 5.7k indexed · 4 hit papers · h-index 37
Topics
Cancer Genomics and Diagnostics (30 papers)Cancer Immunotherapy and Biomarkers (24 papers)Lung Cancer Treatments and Mutations (19 papers)

In The Last Decade

Sophie Postel‐Vinay

109 papers receiving 5.6k citations

Hit Papers

Hyperprogressive Disease Is a New Pattern of Progression ...20162026201920222016201720192024250500750

Peers

Sophie Postel‐Vinay
Comparison fields: 5 of 119
  • Oncology 3.2k
  • Molecular Biology 2.2k
  • Pulmonary and Respiratory Medicine 1.7k
  • Immunology 951
  • Cancer Research 936
Replace Albiruni R. Abdul Razak with:
Albiruni R. Abdul Razak Canada
Kirsten B. Goldberg United States
Marc R. Theoret United States
Julia A. Beaver United States
Fadi Braiteh United States
Michael W. Sill United States
Shenghui Tang United States
Jean‐Pierre Delord France
Michael Smylie Canada
Daniel Castellano Spain
Sophie Postel‐Vinay relative to Albiruni R. Abdul Razak Canada Albiruni R. Abdul Razak's profile →
Citations per field
00.5×4.5×
Albiruni R. Abdul Razak · 1×
Citations per year

Countries citing papers authored by Sophie Postel‐Vinay

Since Specialization
Citations

This map shows the geographic impact of Sophie Postel‐Vinay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Postel‐Vinay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Postel‐Vinay more than expected).

Fields of papers citing papers by Sophie Postel‐Vinay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Postel‐Vinay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Postel‐Vinay. The network helps show where Sophie Postel‐Vinay may publish in the future.

Co-authorship network of co-authors of Sophie Postel‐Vinay

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Postel‐Vinay. A scholar is included among the top collaborators of Sophie Postel‐Vinay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Postel‐Vinay. Sophie Postel‐Vinay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 studybreakdown →
43
3 2
4 19
5 4
6 2
7 1
8 71
9 63
10 5
11 5
12 106
13 41
14 1
15
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1breakdown →
867
16 59
17 15
18 1
19 60
20 69

About Sophie Postel‐Vinay

Sophie Postel‐Vinay is a scholar working on Oncology, Cancer Research and Statistics and Probability, having authored 117 papers that have together received 5.7k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Lung Cancer Treatments and Mutations (19 papers). The work is most often cited by research in Oncology (3.2k citations), Cancer Research (936 citations) and Pulmonary and Respiratory Medicine (1.7k citations). Sophie Postel‐Vinay has collaborated with scholars based in France, United Kingdom and United States. Frequent co-authors include Jean‐Charles Soria, Aurélien Marabelle, Sandrine Aspeslagh, Christophe Massard, Antoine Hollebecque, Stéphane Champiat, Daphné Morel, Samy Ammari, Fabrice André and Laurent Dercle. Their work appears in journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026